CoChat

Comparative assessment of multiple COVID-19 serological technologies supports continued evaluation of point-of-care lateral flow assays in hospital and community healthcare settings

Open access
Pickering, Suzanne, Betancor, Gilberto, Galão, Rui Pedro, Merrick, Blair, Signell, Adrian W., Wilson, Harry D., Kia Ik, Mark Tan, Seow, Jeffrey, Graham, Carl, Acors, Sam, Kouphou, Neophytos, Steel, Kathryn J. A., Hemmings, Oliver, Patel, Amita, Nebbia, Gaia, Douthwaite, Sam, O’Connell, Lorcan, Luptak, Jakub, McCoy, Laura E., Brouwer, Philip, van Gils, Marit J., Sanders, Rogier W., Martinez Nunez, Rocio, Bisnauthsing, Karen, O’Hara, Geraldine, MacMahon, Eithne, Batra, Rahul, Malim, Michael H., Neil, Stuart J. D., Doores, Katie J., Edgeworth, Jonathan D. · 2020 · PLOS Pathogens

Published version of a preprint

Cited by 107

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Abstract

There is a clear requirement for an accurate SARS-CoV-2 antibody test, both as a complement to existing diagnostic capabilities and for determining community seroprevalence. We therefore evaluated the performance of a variety of antibody testing technologies and their potential use as diagnostic tools. Highly specific in-house ELISAs were developed for the detection of anti-spike (S), -receptor binding domain (RBD) and -nucleocapsid (N) antibodies and used for the cross-comparison of ten commercial serological assays-a chemiluminescence-based platform, two ELISAs and seven colloidal gold lateral flow immunoassays (LFIAs)-on an identical panel of 110 SARS-CoV-2-positive samples and 50 pre-pandemic negatives. There was a wide variation in the performance of the different platforms, with specificity ranging from 82% to 100%, and overall sensitivity from 60.9% to 87.3%. However, the head-to-head comparison of multiple sero-diagnostic assays on identical sample sets revealed that performance is highly dependent on the time of sampling, with sensitivities of over 95% seen in several tests when assessing samples from more than 20 days post onset of symptoms. Furthermore, these analyses identified clear outlying samples that were negative in all tests, but were later shown to be from individuals with mildest disease presentation. Rigorous comparison of antibody testing platforms will inform the deployment of point-of-care technologies in healthcare settings and their use in the monitoring of SARS-CoV-2 infections.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1371/journal.ppat.1008817

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 5 references

Research works printed but not linked: 9

  1. KK To, 2020, Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study, Lancet Infect Dis, 20, 565, 10.1016/S1473-3099(20)30196-1 · DOI · Paper page
  2. L Zou, 2020, SARS-CoV-2 Viral Load in Upper Respiratory Specimens of Infected Patients, N Engl J Med, 382, 1177, 10.1056/NEJMc2001737 · DOI · Paper page
  3. L Verdoni, 2020, An outbreak of severe Kawasaki-like disease at the Italian epicentre of the SARS-CoV-2 epidemic: an observational cohort study, Lancet
  4. E Whittaker, 2020, Clinical Characteristics of 58 Children With a Pediatric Inflammatory Multisystem Syndrome Temporally Associated With SARS-CoV-2, JAMA
  5. HE Randolph, 2020, Herd Immunity: Understanding COVID-19, Immunity, 52, 737, 10.1016/j.immuni.2020.04.012 · DOI · Paper page
  6. Whitman JD, Hiatt J, Mowery CT, Shy BR, Yu R, Yamamoto TN, et al. Test performance evaluation of SARS-CoV-2 serological assays. medRxiv 2020.04.25.20074856 [Preprint]. 2020 [cited 2020 May 29]. https://doi.org/10.1101/2020.04.25.20074856. · DOI
  7. Lassaunière R, Frische A, Harboe ZB, Nielsen ACY, Fomsgaard A, Krogfelt, Jørgensen CS. Evaluation of nine commercial SARS-CoV-2 immunoassays. medRxiv 2020.04.09.20056325 [Preprint]. 2020 [cited 2020 May 29]. https://doi.org/10.1101/2020.04.09.20056325. · DOI · Paper page
  8. Tan W, Lu Y, Wang J, Dan Y, Tan Z, He, X, et al. Viral Kinetics and Antibody Responses in Patients with COVID-19. medRxiv 2020.03.24.20042382 [Preprint]. 2020 [cited 2020 May 29]. https://doi.org/10.1101/2020.03.24.20042382. · DOI · Paper page
  9. O Sobolev, 2016, Adjuvented influenza-H1N1 vaccination reveals lymphoid signatures of age-dependent early responses and of clinical adverse events, Nat Immunol, 17, 204, 10.1038/ni.3328 · DOI · Paper page

Cited by

Metadata

Authors
Pickering, S., Betancor, G., Galão, R. P., Merrick, B., Signell, A. W., Wilson, H. D., Kia Ik, M. T., Seow, J., Graham, C., Acors, S., Kouphou, N., Steel, K. J. A., Hemmings, O., Patel, A., Nebbia, G., Douthwaite, S., O’Connell, L., Luptak, J., McCoy, L. E., Brouwer, P., van Gils, M. J., Sanders, R. W., Martinez Nunez, R., Bisnauthsing, K., O’Hara, G., MacMahon, E., Batra, R., Malim, M. H., Neil, S. J. D., Doores, K. J., & Edgeworth, J. D.
Venue
PLOS Pathogens
Published
2020-09-24
Volume
16
Issue
9
Pages
e1008817
ISSN
  • 1553-7366 (ISSN-L)
  • 1553-7374
OpenAlex
W3088689466
Cited by
107
References
5
FWCI
3.02
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.